Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 168

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Cost‐effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C

Open access
Lin, O. S., Keeffe, E. B., Sanders, G. D., Owens, D. K.·2004·Alimentary Pharmacology & Therapeutics

Abstract

Summary: Background : Screening for hepatocellular carcinoma in cirrhotic patients using abdominal ultrasonography and alpha‐foetoprotein levels is widely practiced. Aim : To evaluate its cost‐effectiveness using a Markov decision model. Methods : Several screening strategies with abdominal ultrasonography or computerized tomography and serum alpha‐foetoprotein at 6–12‐month intervals in 40‐year‐old patients with chronic hepatitis C and compensated cirrhosis were simulated from a societal perspective, resulting in discounted costs per quality‐adjusted life‐year saved. Extensive sensitivity analysis was performed. Results : For the least efficacious strategy, annual alpha‐foetoprotein/ultrasonography, the incremental cost‐effectiveness ratio (vs. no screening) was $23 043/quality‐adjusted life‐year. Biannual alpha‐foetoprotein/annual ultrasonography, the most commonly used strategy in the United States, was more efficacious, with a cost‐effectiveness ratio of $33 083/quality‐adjusted life‐year vs. annual alpha‐foetoprotein/ultrasonography. The most efficacious strategy, biannual alpha‐foetoprotein/ultrasonography, resulted in a cost‐effectiveness ratio of $73 789/quality‐adjusted life‐year vs. biannual alpha‐foetoprotein/annual ultrasonography. Biannual alpha‐foetoprotein/annual computerized tomography screening resulted in a cost‐effectiveness ratio of $51 750/quality‐adjusted life‐year vs. biannual alpha‐foetoprotein/annual ultrasonography screening. Conclusions : Screening for hepatocellular carcinoma is as cost‐effective as other accepted screening protocols. Of the strategies evaluated, biannual alpha‐foetoprotein/annual ultrasonography gives the most quality‐adjusted life‐year gain while still maintaining a cost‐effectiveness ratio <$50 000/quality‐adjusted life‐year. Biannual alpha‐foetoprotein/annual computerized tomography screening may be cost‐effective.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2036.2004.01963.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 168

Metadata

Authors
Lin, O. S., Keeffe, E. B., Sanders, G. D., & Owens, D. K.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2004-04-29
Volume
19
Issue
11
Pages
1159-1172
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W2068779367
Cited by
168
References
1
FWCI
18.17
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cost‐effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. https://app.cochat.ai/papers/10.1111/j.1365-2036.2004.01963.x
The paper
Lin, O. S., Keeffe, E. B., Sanders, G. D., & Owens, D. K. (2004). Cost‐effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2004.01963.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.